Grignani et al. explored sorafenib and the combination of sorafenib with the mammalian target of rapamycin (mTOR) inhibitor everolimus [32,42] in patients with unresectable high-grade osteosarcoma and reported promising PFS rates at five months. Here, MTOR is linked to osteosarcoma.